TITLE

REPOSITORY HEPARIN AS AN ANTIATHEROGENIC AGENT

AUTHOR(S)
Cohen, Clifford; Loewe, Leo
PUB. DATE
December 1962
SOURCE
Angiology;Dec1962, Vol. 13 Issue 12, p545
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
1. Impressive evidence is at hand to establish correlation between atherosclerosis and error of lipid metabolism. 2. Major antintherugenic efforts have been expended in efforts to correct the metabolic defect, primarily by dietary control. 3. Dietary control is not the sole answer to the prophylaxis of atherosclerosis. 4. Basic studies have indicated that heparin plays a cardinal role in lipid metabolism. 5. A realistic antiatherogenic program should combine the antilipemic properties of a calculated low fat diet and use of exogenous heparin. 6. A practical method of long term heparin therapy is suggested.
ACCESSION #
16369474

 

Related Articles

  • THE EFFECT OF SUBLINGUAL HEPARIN ON LIPOPROTEIN DISTRIBUTION IN ATHEROSCLEROSIS. Biancani, G. // Angiology;Apr1961, Vol. 12 Issue 4, p119 

    Focuses on the capability of sublingual heparin in restoring the distribution of lipoprotein in the body in the treatment of atherosclerosis. Cause of atherosclerosis; Importance of the clearing factor of the heparin in its capacity in treating atherosclerosis; Developments in the heparin therapy.

  • Guidelines for Heparin Therapy. Genton, Edward // Annals of Internal Medicine;Jan74, Vol. 80 Issue 1, p77 

    Presents guidelines for heparin therapy. Anticoagulant mechanisms of heparin; Route of heparin administration; Counteraction of heparin effect.

  • THE EFFECT OF HEPARIN ON CHOLESTEROL PARTITION, LIPOPROTEINS AND ATHEROSCLEROSIS IN EXPERIMENTAL HYPERCHOLESTEROLEMIA. Moses, Campbell; Rhodes, Grace L. // Angiology;Oct1954, Vol. 5 Issue 5, p429 

    Investigates the effect of heparin on cholesterol partition, lipoproteins and atherosclerosis in experimental hypercholesterolemia. Absence of significant reduction in aortic atherosclerosis in the blood fractions; Failure of heparin to retard the development of atherosclerosis; Impact of high...

  • Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis. Chong, P.H.; Bachenheimer, B.S. // Drugs;Jul2000, Vol. 60 Issue 1, p55 

    The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many patients. The development of the HMG-CoA reductase inhibitors (statins) have been a major advance in that they possess multiple pharmacological effects...

  • A case of probable bemiparin-induced heparin-induced thrombocytopenia type II managed with low-dose fondaparinux. Koul, A. N.; Koufakis, T.; Tsapakidis, K.; Margaritis, A.; Gabranis, I. // Journal of Postgraduate Medicine;Oct-Dec2015, Vol. 61 Issue 4, p267 

    A letter to the editor is presented in response to the article "A Case of Probable Hemiparin-Induced Heparin-Induced Thrombocytopenia (HIT) Type II Managed With Low-Dose Fondaparinux" published in a previous issue.

  • Control and Management of Heparin Therapy in Venous Thromboembolism. Almazán, A.; Lozano, F.; Ramos, M.; Gómez-Alonso, A. // Vascular Surgery;Jan/Feb1983, Vol. 17 Issue 1, p1 

    The precise management of Deep Venous Thrombosis (DVT), and its complications, is of considerable clinical importance as well as being a controversial topic. However, the standard treatment or complementary of others, as well as the one accepted as being of less risk and more effectiveness is...

  • Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations. Leong, Wendy; Hoppensteadt, Debra A. // Clinical & Applied Thrombosis/Hemostasis;Oct2003, Vol. 9 Issue 4, p293 

    This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.

  • Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. Warkentin, Theodore E.; Levine, Mark N.; Hirsh, Jack; Horsewood, Peter; Roberts, Robin S.; Gent, Michael; Kelton, John G. // New England Journal of Medicine;5/18/95, Vol. 332 Issue 20, p1330 

    Background: Heparin-induced thrombocytopenia, defined by the presence of heparin-dependent IgG antibodies, typically occurs five or more days after the start of heparin therapy and can be complicated by thrombotic events. The frequency of heparin-induced thrombocytopenia and of heparin-dependent...

  • Increased bleeding with GPIIb-IIIa antagonist use.  // Reactions Weekly;4/1/2006, Issue 1095, p4 

    Presents information on the increased bleeding caused by GPIIb-IIIa antagonist use. Type of treatment which can reduce the bleeding caused by the antagonist; Methods used to assess the safety and efficacy of enoxaparin over heparin; Link between the sheath size caused by using closure devices...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics